Biochemical abnormality in erythropoietic protoporphyria: Cause and consequences

被引:4
作者
Bloomer, Joseph R.
Wang, Yongming
Singhal, Anuj
Risheg, Hiba
机构
[1] Univ Alabama, UAB Liver Ctr, Dept Med, Birmingham, AL 35294 USA
[2] Univ Alabama, UAB Liver Ctr, Dept Genet, Birmingham, AL 35294 USA
关键词
erythropoietic protoporphyria; heme biosynthesis; ferrochelatase activity; ferrochelatase DNA analysis;
D O I
10.1097/01.mpg.0000226388.56612.fa
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Erythropoietic protoporphyria (EPP) is a genetic disorder in which deficient ferrochelatase (FECH) activity causes the excessive production and excretion of protoporphyrin. This in turn causes the major clinical manifestation of EPP, photosensitivity and, in some patients, hepatobiliary disease that may be severe. The objective of this study was to define genotypic determinants of phenotype in EPP. Methods: FECH activity was measured in 30 tissue samples from 26 patients with symptomatic EPP to determine the degree of deficient activity. FECH DNA analysis was also done in 26 families with EPP to identify mutations and examine for the presence of a polymorphism (IVS3-48c) that causes low gene expression. Results: The level of residual FECH activity that was measured in tissue samples of patients with symptomatic EPP was <= 30% of the mean normal level in all patients except one. Lowest levels (4-20% normal) were in patients with advanced EPP liver disease. Heterozygous FECH mutations were found in 45 individuals from 26 families with EPP. In 94% of the 32 symptomatic individuals, 15 of whom had liver disease, the polymorphism was present in the nonmutant allele. In 13 asymptomatic patients, the polymorphism was absent. Conclusions: Patients with symptomatic EPP (photosensitivity with/without hepatobiliary disease) usually have a mutation in I FECH allele that alters enzyme structure/ function, together with a polymorphism in the nonmutant allele that causes low gene expression. This leads to a significant reduction in FECH activity that causes symptomatic disease to develop because of the excess protoporphyrin produced.
引用
收藏
页码:S36 / S40
页数:5
相关论文
共 31 条
[1]   PROTOPORPHYRIN-INDUCED CHOLESTASIS IN THE ISOLATED INSITU PERFUSED-RAT-LIVER [J].
AVNER, DL ;
LEE, RG ;
BERENSON, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (02) :385-394
[2]   Relationship between biliary lipid and protoporphyrin secretion; Potential role of mdr2 P-glycoprotein in hepatobiliary organic anion transport [J].
Beukeveld, GJJ ;
Veld, GI ;
Havinga, R ;
Groen, AK ;
Wolthers, BG ;
Kuipers, F .
JOURNAL OF HEPATOLOGY, 1996, 24 (03) :343-352
[3]   Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation [J].
Bloomer, J ;
Bruzzone, C ;
Zhu, L ;
Scarlett, Y ;
Magness, S ;
Brenner, D .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :107-114
[4]  
Bloomer J R, 2000, Trans Am Clin Climatol Assoc, V111, P245
[5]   HEPATIC DISEASE IN ERYTHROPOIETIC PROTOPORPHYRIA [J].
BLOOMER, JR ;
PHILLIPS, MJ ;
DAVIDSON, DL ;
KLATSKIN, G .
AMERICAN JOURNAL OF MEDICINE, 1975, 58 (06) :869-882
[6]   FATAL LIVER-FAILURE IN PROTOPORPHYRIA - SYNERGISM BETWEEN ETHANOL EXCESS AND THE GENETIC-DEFECT [J].
BONKOVSKY, HL ;
SCHNED, AR .
GASTROENTEROLOGY, 1986, 90 (01) :191-201
[7]   HEME SYNTHETASE DEFICIENCY IN HUMAN PROTOPORPHYRIA - DEMONSTRATION OF DEFECT IN LIVER AND CULTURED SKIN FIBROBLASTS [J].
BONKOWSKY, HL ;
BLOOMER, JR ;
EBERT, PS ;
MAHONEY, MJ .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (05) :1139-1148
[8]  
BOTTOMLEY SS, 1975, J LAB CLIN MED, V86, P126
[9]  
Chen FP, 2002, CELL MOL BIOL, V48, P83
[10]   HEPATOBILIARY IMPLICATIONS AND COMPLICATIONS IN PROTOPORPHYRIA, A 20-YEAR STUDY [J].
DOSS, MO ;
FRANK, M .
CLINICAL BIOCHEMISTRY, 1989, 22 (03) :223-229